Shots:

• The approval of Anjeso is based on two P-III studies assessing Anjeso (30mg- bolus injection) following Major Surgery and Abdominoplasty Surgery vs PBO in ratio (1:1) in 932 patients
• The study demonstrated well tolerated results- also achieved 15 of the 19 secondary endpoints- plus statistically significant differences in SPID6- SPID12- SPID24- SPID24-48 with no serious adverse events
• Anjeso (meloxicam) injection is a long-acting- preferential COX-2 inhibitor that possess analgesic- anti-inflammatory and antipyretic activities also approved by the US FDA in Feb-2020 for moderate to severe pain- alone or in combination with other non-NSAID analgesics

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Twitter